 |
|
|
|
 |
|
|
| Article 1 to 10 out of 14 concerning GPC Biotech AG
|
-
GPC Biotech Reports that Marketing Authorization Application for Satraplatin is to be Withdrawn
(29 Jul 2008)
GPC Biotech AG reported that the Company has been informed by its partner for satraplatin in Europe that they plan to withdraw the Marketing Authorization Application (MAA) for satraplatin plus prednisone for the treatment of hormone-refractory ...
-
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes
(17 Jun 2008)
GPC Biotech AG announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, an oral platinum compound. The patent is entitled, "Satraplatin for treating resistant or refractory tumors" and covers certain uses of satraplatin ...
-
GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer
(05 Dec 2007)
GPC Biotech AG announced the appointment of Torsten Hombeck, Ph.D., to Chief Financial Officer. Dr. Hombeck will assume his duties on January 1, 2008. Dr. Hombeck will replace Mirko Scherer, Ph.D., who is resigning from the Company, effective ...
-
GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval
(01 Aug 2007)
Company Plans to Resubmit Application Pending Final Survival Analysis
GPC Biotech AG announced that it has withdrawn the satraplatin capsules New Drug Application (NDA) filed for accelerated approval for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed. The Company based ...
-
GPC Biotech AG Named in Purported Class Action Lawsuit in the United States
(31 Jul 2007)
GPC Biotech AG announced that it has been sued in the United States District Court for the Southern District of New York, purportedly in a class action lawsuit on behalf of all persons who purchased or acquired securities of GPC Biotech between ...
-
GPC Biotech Consolidates Drug Discovery Activities
(08 May 2007)
Waltham, Massachusetts Facility to be Closed
GPC Biotech AG announced that it is consolidating its drug discovery efforts to one location. This consolidation involves closing the Company's facility in Waltham, Massachusetts and a staff reduction involving approximately 16% of the Company's ...
-
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
(17 Apr 2007)
GPC Biotech AG announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) ...
-
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
(20 Feb 2007)
GPC Biotech AG announced that the Company has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for satraplatin for the treatment of patients with androgen independent (hormone ...
-
European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody
(17 Feb 2006)
GPC Biotech AG announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended the granting of orphan medicinal product designation for the anticancer monoclonal antibody 1D09C3 for the ...
-
GPC Biotech Announces Clearance to Initiate Additional Phase 1 Clinical Trial with 1D09C3 Anticancer Monoclonal Antibody
(10 Nov 2005)
GPC Biotech AG announced that it had received clearance from the Paul-Ehrlich-Institut (PEI) to initiate human clinical testing in Germany with the 1D09C3 anticancer monoclonal antibody. The PEI is the German national agency responsible for ...
Additional information
GPC Biotech AG
Martinsried, Germany
Company
|
|
|
|
|
|
Top
